Oura is reportedly eyeing a September IPO that could value it at more than $16B

In a statement to TechCrunch sent over the weekend, a spokesperson pushed back against claims in that suit, saying the company plans to “defend against them in the appropriate legal forum” and that: “While Oura Ring is not a medical device or a substitute for a clinical sleep study, Oura’s sleep staging has been validated and compared favorably in multiple studies against polysomnography, the gold standard.” The statement continued on to say that “ultiple third-party, independent studies support our claims of accuracy and we have transparently reported on the mechanisms and measures that inform Oura’s sleep staging.”